Key Insights on CYTK Stock – What Investors Should Know

By Emilio Sanchez • Wednesday, October 09 10:13 • Permanent Link

More and more people are talking about Cytokinetics over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $55.37? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Cytokinetics has moved 51.1% over the last year, and the S&P 500 logged a change of 31.4%
CYTK has an average analyst rating of buy and is -31.35% away from its mean target price of $80.65 per share
Its trailing earnings per share (EPS) is $-5.36
Cytokinetics has a trailing 12 month Price to Earnings (P/E) ratio of -10.3 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $-4.9 and its forward P/E ratio is -11.3
The company has a Price to Book (P/B) ratio of 59.92 in contrast to the S&P 500's average ratio of 4.74
Cytokinetics is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
The company has a free cash flow of $-233928256, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.